Bayer HealthCare / Press

Two-Year Results From Phase 3 Trial Show Sustained Improvement in Vision for People with Diabetic Macular Edema

Bayer HealthCare today announced that in the Phase 3 VIVID-DME trial of aflibercept solution for injection into the eye for the treatment of vision impairment due to diabetic macular edema, aflibercept solution for injection 2 milligrams, in both treatment groups, showed a sustained improvement from baseline in best corrected visual acuity at week 100, compared to laser photocoagulation. more      

In Focus

Healthcare News

Photos & Videos

  • Photos

    Photo galleries with topic-related images.

  • TV Footage

    In this section you can find videos for editorial coverage.

Bayer HealthCare Links

RSS Feed
RSS Feed

Copyright © Bayer HealthCare AG